Protagonist Therapeutics, Inc. Net Income 2014–2025
Protagonist Therapeutics, Inc. reported $-130.15M of net income for fiscal 2025. That was 147.3% lower than fiscal 2024. Compared with fiscal 2020, the change was -96.7%.
| Fiscal year | Net Income | Net margin | Change (YoY) |
|---|---|---|---|
| FY 2025 | $-130.15M | -282.8% | -147.3% |
| FY 2024 | $275.19M | 63.3% | +448.5% |
| FY 2023 | $-78.95M | -131.6% | +38.0% |
| FY 2022 | $-127.39M | -479.3% | -1.5% |
| FY 2021 | $-125.55M | -458.9% | -89.8% |
| FY 2020 | $-66.15M | -231.1% | +14.3% |
| FY 2019 | $-77.19M | -33414.3% | -98.3% |
| FY 2018 | $-38.92M | -125.9% | -5.3% |
| FY 2017 | $-36.96M | -184.2% | +0.6% |
| FY 2016 | $-37.18M | — | -150.2% |
| FY 2015 | $-14.86M | — | -34.2% |
| FY 2014 | $-11.07M | — | — |
Source: Protagonist Therapeutics, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open PTGX 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Protagonist Therapeutics, Inc. reported $-130.15M of net income for fiscal 2025. That was 147.3% lower than fiscal 2024. Compared with fiscal 2020, the change was -96.7%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Protagonist Therapeutics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeProtagonist Therapeutics, Inc. — frequently asked questions
What is Protagonist Therapeutics, Inc.'s net income?
Protagonist Therapeutics, Inc. (PTGX) reported net income of $-130.15M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Protagonist Therapeutics, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.